shares of tandem diabetes care inc were trading lower on the nasdaq thursday a day after the company released firstquarter financial results that showed a wider loss per share than expected by analysts at 1212 pm et the companys stock had fallen 1391 to trade at 8129 per share after the bell wednesday tandem reported a firstquarter loss per share of 23 cents on sales of 1759 million analysts were expecting a loss per share of 7 cents on sales of 1682 million according to factset in the yearago period the company reported a loss per share of 8 cents on sales of 141 million also on wednesday the company said it was expecting 2022 sales in a range of 850 million to 865 million previously the company said it was expecting sales in a range of 845 million to 860 million on thursday svb leerink cut its price target on tandems stock to 110 per share from 120 piper sandler cut its target to 120 per share from 170 and raymond james cut its price target to 125 per share from 138 as reported by benzinga